![]() ![]() The consumer discretionary sector was also a winner, rising by 19.25% year-to-date as of May 31. The communications services sector also managed to pull through, rising by 32.25% over the same period. He noted that the S&P 500 technology sector has been winning in May, rising by 34.81% year-to-date as of May 31. In another Mad Money episode that aired May 31, Cramer went through several S&P 500 sectors, sifting through the winners and the losers for his audience to be better prepared for this market. ![]() This preference for the company may very well stem from the fact that NVIDIA Corporation (NASDAQ:NVDA) seems to have "zero competition in the chip space," as Cramer himself noted.īut apart from NVIDIA Corporation (NASDAQ:NVDA), Cramer is also heavily bullish on many other companies, such as ON Semiconductor Corporation (NASDAQ: ON ) and Bristol-Myers Squibb Company (NYSE: BMY ). However, according to Cramer, NVIDIA Corporation's (NASDAQ:NVDA) Huang had told him years ago that "Moore's law was dead." He made this claim on the basis of the fact that "he came up with a way to make graphics cards that were more powerful and even more efficient, even if they were bigger because there was increasingly no benefit to shrinking semiconductors."īecause of NVIDIA Corporation's (NASDAQ:NVDA) undeniable success and its superior chips, major big tech companies have begun relying on it alone for their chips, especially if artificial intelligence is a space they wish to venture into. To read this article on click here.While going over the potential NVIDIA Corporation (NASDAQ:NVDA) harnesses, Cramer mentioned Moore's law, a theory that implies that "chips will double in power every two years." This is a rule that has been governing the chip space for decades, placing limitations on what chip-makers can do. Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Investors should take the time to consider JAZZ for their portfolios due to its solid Zacks Ranks, notable earnings and valuation metrics, and impressive Value and VGM Style Scores. JAZZ has an average earnings surprise of 12.8%. The Zacks Consensus Estimate has increased $0.57 to $17.05 per share. 11 analysts revised their earnings estimate upwards in the last 60 days for fiscal 2022. Value investors don't just pay attention to a company's valuation ratios positive earnings play a crucial role, too. Shares of Jazz Pharmaceuticals are trading at a forward earnings multiple of 8.8X, as well as a PEG Ratio of 1.1, a Price/Cash Flow ratio of 6.5X, and a Price/Sales ratio of 2.8X. ![]() JAZZ boasts a Value Style Score of A and VGM Score of A, and holds a Zacks Rank #3 (Hold) rating. Xywav was also approved for treating idiopathic hypersomnia (IH). Both drugs are approved for treating cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients. Xywav is a low-sodium formulation of Jazz’s legacy drug, Xyrem, which was launched in 2020. The company derives the majority of its revenues from its sleep disorder drugs - Xywav and Xyrem. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to help pick out the most attractive and discounted stocks.ĭublin, Ireland-based Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience and oncology. Different than growth or momentum investors, value-focused investors are all about finding good stocks at good prices, and discovering which companies are trading under what their true value is before the broader market catches on.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |